Key Points
- The market continues to bounce back and forth as investors wait on news from the Federal Reserve later this month.
- Next week’s reading of the PCE Index may be the next market mover.
- Here are some of our most popular articles from this week.
- 5 stocks we like better than QuantumScape
Will they or won’t they? The “they” is the Federal Reserve, and the question is what the Fed will say about the direction of interest rates when they meet later this month. Investors are starting to cool on the idea that the Fed will cut rates in March. But the Fed itself continues to suggest that the economy may be cooling.
In the meantime, Apple Inc. NASDAQ: AAPL lifted the market on news that it avoided litigation surrounding its Apple Watch. But the rally may be short-lived. Next week, investors will get the latest read on the Personal Consumption Expenditures (PCE) index, which is likely to show inflation ticking higher, which could dampen investor sentiment. However, investors will get a different read on consumer spending when Visa Inc. NYSE: V reports earnings late next week.
Here are some of the top stories the MarketBeat team covered this week.
Articles by Jea Yu
Earnings season is underway, which has investors looking at the guidance from the companies’ reporting. A common tactic is to underpromise and overdeliver. So, it’s noteworthy when companies raise their guidance. That’s the case with three healthcare companies that Jea Yu writes about this week. Each company offers buying opportunities after raising its revenue guidance for the coming year.
Solid-state batteries are a potential alternative to lithium-ion batteries. QuantumScape Co. NYSE: QS is the leader in this space. Yu wrote about the good news that gave QS stock a lift this week, why it could be forming a bullish technical signal, and why investors may still need to proceed cautiously.
If you think the weight loss craze is flaming out, think again. Yu writes about two biotech stocks with weight loss drugs in late-stage clinical trials. Read about the chances these drugs may have to compete with Ozempic or Mounjaro.
Articles by Thomas Hughes
Per tradition, the banks have been the first to report earnings. As Thomas Hughes writes, the strength of the big bank stocks was largely priced into the market. However, that creates an opportunity to buy the dip in small regional banks like the three high-yielding bank stocks he analyzes this week.
Cybersecurity will continue to be an essential component of every home and business. But some cybersecurity stocks have soared into correction territory. This week, Hughes writes about two cybersecurity stocks that are due for a correction but will be solid buying opportunities for patient investors.
The chip sector continues to rebound from an oversupplied situation in 2023. Although Nvidia Corporation NASDAQ: NVDA remains a solid choice, Hughes analyzes why Advanced Micro Devices Inc. NASDAQ: AMD has an upside that may rival 2023 NVDA stock.
Articles by Sam Quirke
Quirke was also writing about , which remains a popular name among chip stocks. Nevertheless, QCOM stock has been lagging behind other stocks in the sector, but based on, you guessed it, a bullish outlook from analysts.
Articles by Kate Stalter
It’s been a rough start to the year for the electric vehicle (EV) sector and EV stocks, with Tesla Inc. NASDAQ: TSLA leading the way with a 13% decline. This week, Kate Stalter outlines the current state of play with the EV market and how that may affect the future outlook for TSLA stock.
The troubles in the EV sector are a gut punch for growth investors. But as Stalter explains, several companies are already announcing double-digit dividend increases. This means that dividend-paying stocks, which had a rough year in 2023, could be
Articles by Ryan Hasson
has taken investors on a roller coaster ride since 2020. Off a year in which PYPL stock fell almost 20%, Ryan Hasson writes about the neutral outlook for the stock heading into earnings and why .
Hasson also wrote about the steep drop in Spirit Airlines Inc. NASDAQ: SAVE after the Justice Department blocked its merger with JetBlue Airways Corporation NASDAQ: JBLU. The decision reminds investors not to put much stock in merger announcements until the deal is done.
Articles by Gabriel Osorio-Mazilli
Inflation is being felt in many ways. One of the ones drawing significant attention in 2024 is rising insurance premiums. However, Gabriel Osorio-Mazilli explains why that may be bullish for UnitedHealth Group Inc. NYSE: UNH. The company faces rising medical costs, but its ability to raise premiums allows it to pass much of those along to consumers.
Many investors sold the news from The Boeing Company NYSE: BA after the in-flight incident with its MAX 9 jet. However, Osorio-Mazilli explains why investors who are paying attention to analyst sentiment may want to take advantage of oversold conditions in BA stock.
And while consumers and businesses have been enjoying the relief that comes from lower oil prices, Osorio-Mazilli explains why the oil market is setting up for a major rally in 2024 and gives you a short list of oil stocks to buy.
Articles by MarketBeat Staff
As dividend investors know, a high yield doesn’t always make a stock or an ETF a good value. However, this week, the MarketBeat staff identified three high yield ETFs that look like good buys in 2024.
If picking individual dividend stocks is more your flavor, the staff shows you how it used the MarketBeat dividend screener to find three stocks that were garnering positive news sentiment in the last month.
And as earnings season rolls on, we’ll be hearing from restaurant stocks and, specifically, fast food stocks. This week, the MarketBeat staff analyzed three of the top names in the fast food sector and forecasted what you should expect from their upcoming earnings.
Before you consider QuantumScape, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and QuantumScape wasn’t on the list.
While QuantumScape currently has a “Reduce” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.